USA - NASDAQ:OMCL - US68213N1090 - Common Stock
The current stock price of OMCL is 33.58 USD. In the past month the price increased by 12.01%. In the past year, price decreased by -31%.
|  Symbol  |  Company Name  |  TA  |  FA  |  PE  |  Market Cap  | 
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.98 | 216.98B | ||
| ISRG | INTUITIVE SURGICAL INC | 61.56 | 190.00B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.09 | 149.02B | ||
| SYK | STRYKER CORP | 28.71 | 141.06B | ||
| MDT | MEDTRONIC PLC | 16.45 | 116.69B | ||
| BDX | BECTON DICKINSON AND CO | 12.57 | 51.42B | ||
| IDXX | IDEXX LABORATORIES INC | 52.33 | 50.28B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.48 | 49.01B | ||
| RMD | RESMED INC | 26.41 | 36.81B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.34 | 34.24B | ||
| DXCM | DEXCOM INC | 40.12 | 26.75B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.23 | 26.26B | 
 Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. The company is headquartered in Fort Worth, Texas and currently employs 3,650 full-time employees. The company went IPO on 2001-08-08. The firm is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
OMNICELL INC
4220 North Freeway
Fort Worth TEXAS 94043 US
CEO: Randall A. Lipps
Employees: 3670
Phone: 18774159990
Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. The company is headquartered in Fort Worth, Texas and currently employs 3,650 full-time employees. The company went IPO on 2001-08-08. The firm is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
The current stock price of OMCL is 33.58 USD. The price increased by 13.56% in the last trading session.
OMCL does not pay a dividend.
OMCL has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
OMCL stock is listed on the Nasdaq exchange.
The Revenue of OMNICELL INC (OMCL) is expected to grow by 4.08% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
The outstanding short interest for OMNICELL INC (OMCL) is 4.28% of its float.
ChartMill assigns a technical rating of 4 / 10 to OMCL. When comparing the yearly performance of all stocks, OMCL is a bad performer in the overall market: 80.52% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to OMCL. Both the profitability and the financial health of OMCL get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months OMCL reported a non-GAAP Earnings per Share(EPS) of 1.87. The EPS increased by 25.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.01% | ||
| ROA | 1.08% | ||
| ROE | 1.83% | ||
| Debt/Equity | 0.13 | 
14 analysts have analysed OMCL and the average price target is 44.88 USD. This implies a price increase of 33.65% is expected in the next year compared to the current price of 33.58.
For the next year, analysts expect an EPS growth of -6.93% and a revenue growth 4.08% for OMCL